Literature DB >> 10528787

Fusidic acid in skin and soft tissue infections.

D Spelman1.   

Abstract

Skin and soft skin tissue infections are usually caused by Staphylococcus aureus and Streptococcus pyogenes. In vitro data show good activity of fusidic acid against staphylococci but the minimal inhibitory concentrations for streptococci are relatively high indicating marginal activity. A limited number of clinical trials have been performed using oral fusidic acid and although all have methodological problems the difference in susceptibility of these two organisms is apparent. The end of study cure rates for these studies were 91-99% for S. aureus and 75-85% for S. pyogenes. Topical therapy has been used in a number of forms and for different skin infections. Comparative studies have been conducted with mupirocin, trimethoprim/polymixin cream, hydrogen peroxide and combination steroid preparations. For most of these studies fusidic acid was equivalent to the comparator agent except where there was a proven S. pyogenes infection. Studies with topical fusidic acid have also been reported in specific disease states such as acne, erythrasma, and abscesses with good results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528787     DOI: 10.1016/s0924-8579(98)00074-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes.

Authors:  Elisabeth Kugelberg; Tobias Norström; Thomas K Petersen; Tore Duvold; Dan I Andersson; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 2.  Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.

Authors:  Prabhavathi Fernandes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

3.  Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.

Authors:  Jonas Lannergård; Tobias Norström; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

4.  Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.

Authors:  Tobias Norström; Jonas Lannergård; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

Review 5.  Fusidic acid resistance in Staphylococcus aureus.

Authors:  D Dobie; J Gray
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

6.  Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus.

Authors:  Matthew J Ellington; Sandra Reuter; Simon R Harris; Matthew T G Holden; Edward J Cartwright; Daniel Greaves; Sarah M Gerver; Russell Hope; Nicholas M Brown; M Estee Török; Julian Parkhill; Claudio U Köser; Sharon J Peacock
Journal:  Int J Antimicrob Agents       Date:  2015-02-19       Impact factor: 5.283

Review 7.  Impetigo - review.

Authors:  Luciana Baptista Pereira
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

8.  Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies.

Authors:  Varsha Narayanan; Salman Motlekar; Ganesh Kadhe; Seema Bhagat
Journal:  Dermatol Ther (Heidelb)       Date:  2014-09-12

9.  Polymorphism in Commercial Sources of Fusidic Acid: A Comparative Study of the In Vitro Release Characteristics of Forms I and III from a Marketed Pharmaceutical Cream.

Authors:  Jonathan Byrne; Robert Reinhardt; Trinidad Velasco-Torrijos
Journal:  J Anal Methods Chem       Date:  2017-09-17       Impact factor: 2.193

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.